NTRA · Natera, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-10 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.23 to $325.46 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
6,000 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $309.9250 to $310.5250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
400 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. |
Common Stock
|
100 |
| 2026-08-07 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. |
Common Stock
(I)
|
2,000 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.5950 to $313.3150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
900 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. |
Common Stock
|
100 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. |
Common Stock
|
489 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.10 to $316.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
5,111 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.5050 to $312.5000 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
400 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.04 to $315.67 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
600 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.62 to $318.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
200 |
| 2026-08-07 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.9500 to $314.7150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
850 |
| 2026-08-04 | Brophy Michael Burkes |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025. |
Common Stock
|
478 |
| 2026-08-03 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.27 to $265.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
192 |
| 2026-08-03 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.1500 to $261.8250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
200 |
| 2026-08-03 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.29 to $264.24 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
676 |
| 2026-08-03 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026. |
Common Stock
|
80 |
| 2026-08-03 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.58 to $267.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
296 |
| 2026-08-03 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.63 to $268.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
128 |
| 2026-08-03 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6550 to $264.2400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
947 |
| 2026-08-03 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.1550 to $268.1150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,233 |
| 2026-08-03 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. |
Common Stock
|
300 |
| 2026-08-03 | RABINOWITZ DANIEL |
SEC. AND CHIEF LEGAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. |
Common Stock
|
334 |
| 2026-08-03 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026. |
Common Stock
|
70 |
| 2026-08-03 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.8350 to $268.7700 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
612 |
| 2026-08-03 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. |
Common Stock
|
1,182 |
| 2026-08-03 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026. |
Common Stock
|
160 |
| 2026-08-03 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. |
Common Stock
|
731 |
| 2026-08-03 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. |
Common Stock
|
109 |
| 2026-08-03 | Brophy Michael Burkes |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. |
Common Stock
|
317 |
| 2026-08-03 | Fesko John |
PRESIDENT, CHIEF BUS. OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. |
Common Stock
|
295 |
| 2026-08-03 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025. |
Common Stock
|
410 |
| 2026-07-29 | Brophy Michael Burkes |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025. |
Common Stock
|
1,863 |
| 2026-07-28 | Brophy Michael Burkes |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.32 to $254.3550 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
170 |
| 2026-07-28 | Brophy Michael Burkes |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.0696 to $254.3500 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,241 |
| 2026-07-28 | Brophy Michael Burkes |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.32 to $254.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,008 |
| 2026-07-28 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. |
Common Stock
|
191 |
| 2026-07-28 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.0696 to $254.3500 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
3,580 |
| 2026-07-28 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.0696 to $254.3500 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,204 |
| 2026-07-28 | RABINOWITZ DANIEL |
SEC. AND CHIEF LEGAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.0696 to $254.3500 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,003 |
| 2026-07-28 | Fesko John |
PRESIDENT, CHIEF BUS. OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.0696 to $254.3500 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
931 |
| 2026-07-27 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. |
Common Stock
|
288 |
| 2026-07-27 | Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. |
Common Stock
|
1,010 |
| 2026-07-27 | Rabinowitz Matthew |
Director, EXECUTIVE CHAIRMAN |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. |
Common Stock
|
1,718 |
| 2026-07-27 | Brophy Michael Burkes |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. |
Common Stock
|
782 |
| 2026-07-27 | Fesko John |
PRESIDENT, CHIEF BUS. OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. |
Common Stock
|
782 |
| 2026-07-27 | RABINOWITZ DANIEL |
SEC. AND CHIEF LEGAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. |
Common Stock
|
884 |
| 2026-07-27 | Chapman Steven Leonard |
Director, CEO AND PRESIDENT |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted January 26, 2024. |
Common Stock
|
2,190 |
| 2026-07-15 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.56 to $273.42 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
390 |
| 2026-07-15 | Sheena Jonathan |
Director |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.99 to $275.65 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. |
Common Stock
(I)
|
170 |